Eisai

Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Sun, 03/12/23 - 09:40 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA sets July decision date for full approval of Leqembi
BioSpace
Mon, 03/6/23 - 12:11 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
Wed, 03/1/23 - 06:55 pm
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Thu, 02/23/23 - 04:27 pm
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Eisai Anticipates Full Approval of Leqembi as Early as July
BioSpace
Mon, 02/20/23 - 12:44 pm
Eisai
FDA
Alzheimer's disease
Leqembi
lecanemab
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
Thu, 02/16/23 - 11:18 am
layoffs
Grifols
Frequency Therapeutics
Eliem Therapeutics
Aligos Therapeutics
Thermo Fisher Scientific
Magenta Therapeutics
Eisai
Amgen
Y-mAbs Therapeutics
Century Therapeutics
Elevation Oncology
Calithera Biosciences
Editas Medicine
Verily
Abzena
Eisai gives first glimpse into Alzheimer’s drug launch
BioPharma Dive
Mon, 02/6/23 - 06:21 pm
Eisai
Alzheimer's disease
drug launches
Leqembi
With all eyes on new Alzheimer's med, Eisai lays off 91 staffers on its Fycompa team
Fierce Pharma
Fri, 02/3/23 - 11:03 am
Eisai
Fycompa
layoffs
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Motley Fool
Thu, 01/19/23 - 10:15 am
Biogen
Eisai
Alzheimer's disease
Leqembi
lecanemab
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
Fri, 01/13/23 - 10:49 am
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
After FDA nod, Eisai and Biogen file lecanemab in EU
Pharmaphorum
Wed, 01/11/23 - 11:04 pm
Eisai
Biogen
lecanemab
Europe
Alzheimer's disease
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Mon, 01/9/23 - 10:35 am
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
drug pricing
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
BioPharma Dive
Sun, 01/8/23 - 10:04 pm
Eisai
Biogen
drug pricing
Leqembi
Alzheimer's disease
lecanemab
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
BioPharma Dive
Fri, 01/6/23 - 03:40 pm
Eisai
Biogen
lecanemab
Leqembi
Alzheimer's disease
FDA
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Stat
Thu, 12/22/22 - 11:10 am
Biogen
Eisai
Alzheimer's disease
drug pricing
ICER
lecanemab
3rd patient death potentially tied to Eisai's Alzheimer's drug reported
Fierce Biotech
Thu, 12/22/22 - 11:05 am
Biogen
Eisai
Alzheimer's disease
clinical trials
patient deaths
lecanemab
With bigger fish to fry, Eisai unloads US rights to epilepsy drug Fycompa to Catalyst
Fierce Pharma
Tue, 12/20/22 - 11:14 am
Eisai
Fycompa
Catalyst Pharmaceuticals
epilepsy
CTAD 2022 – lecanemab data hold up, with a big but
EP Vantage
Thu, 12/1/22 - 07:01 pm
Biogen
Eisai
Alzheimer's disease
CTAD
lecanemab
clinical trials
What to make of Eisai and Biogen’s latest Alzheimer’s drug data
BioPharma Dive
Tue, 11/29/22 - 10:58 pm
Biogen
Eisai
Alzheimer's disease
lecanemab

Pages